The State Drug Administration issued a notice: 20 batches of drugs do not meet the regulations

According to the State Drug Administration, after the inspection of 6 pharmaceutical inspection institutions including the China Food and Drug Inspection Research Institute, 20 batches of drugs such as the purple grass produced by 9 companies such as Zhengzhou Ruilong Pharmaceutical Co., Ltd. did not meet the regulations. The relevant situation is notified as follows:

I. Testing by the Institute of Food and Drug Quality Inspection and Research Institute of Food and Drug Quality Inspection, which is marked with the two batches of dihydroxolblytic alkali injection liquid produced by Shanxi Taiyuan Pharmaceutical Co., Ltd. (Yuan Taiyuan Pharmaceutical Factory), did not meet the regulations, and did not meet the requirements of the regulations. Essence

After inspection by the Jilin Provincial Academy of Pharmaceutical Inspection and Research, a batch of agarwood stagnation pills produced by Hebei Bianzhang Pharmaceutical Co., Ltd. did not meet the requirements, and did not meet the requirements of the specified project as the difference in volume.

After inspection by Jiangxi Pharmaceutical Inspection and Inspection and Research Institute, it is marked that the three batches of Huoxiang Zhengqi water produced by Sichuan Tianfu Kangda Pharmaceutical Group Mansion Group and Tai Chi Group Sichuan Nanchong Pharmaceutical Co., Ltd. do not meet the requirements, and the project does not meet the regulations. Monol amount.

It was tested by the Guangdong Pharmaceutical Inspection Institute, and a batch of Longze Xiong Bile Capsules produced by Changchun Puhua Pharmaceutical Co., Ltd. did not meet the regulations and did not meet the requirements of the regulations as microbial limits.

The three batches of chrysanthemum chrysanthemums produced by Yancheng Traditional Chinese Medicine Drinking Piection Co., Ltd. did not meet the regulations and did not meet the requirements of the regulations as the disabled pesticide residue.

After inspection by the Gansu Provincial Academy of Pharmaceutical Inspection and Research, a batch of Qiancao produced by Yunnan Jian'antang Biotechnology Co., Ltd. does not meet the regulations, and does not meet the requirements of the specified projects including traits and identification; Two batches of Qiancao do not meet the requirements, and do not meet the specified projects include traits, identification, total ash, acid insoluble gray, and immersion.

After inspection by the China Food and Drug Inspection Research Institute, a batch of purple grass produced by Guilin Zhongnan (Luzhou) Pharmaceutical Technology Co., Ltd. does not meet the regulations and does not meet the requirements of the specified project as a measurement. The six batches of purple grass do not meet the regulations and do not meet the requirements of the specified projects.

2. For the above -mentioned do not meet the prescribed drugs, the drug supervision and management department has required relevant enterprises and units to take risk control measures such as suspension of sales, recall, and recall, and conduct investigations and rectification on reasons for not compliance.

3. The State Drug Administration requires relevant provincial drug supervision and management departments to organize investigations on suspected illegal acts existing above -mentioned enterprises and units in accordance with the "Drug Administration Law of the People's Republic of China", and publicize the results of the investigation and punishment in accordance with regulations.

(Source: CCTV News Client)

【Edit: Yao Hao】

For more exciting content, please download the "Da Wuhan" client in the major application markets.

- END -